Akashi restarting development of DMD candidate

Akashi Therapeutics Inc. (Cambridge, Mass.) said FDA granted the company clearance to resume clinical development of Duchenne muscular dystrophy candidate HT-100. The company said it intends to start a new Phase IIa trial “as quickly as possible.”

In January 2016, Akashi said it suspended dosing and enrollment in all HT-100 trials after a patient in the Phase I/II HALO study experienced “serious, life-threatening health issues." The patient later died (see BioCentury Extra, Jan. 26, 2016)...